Financhill
Back

Pliant Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Buy
52

PLRX
Pliant Therapeutics

Last Price:
13.83
Seasonality Move:
15.67%

7 Day Trial

ALL ACCESS PASS

$ 7

"This Changes Everything" - Trump Hands Millions Massive IRS Gift

Learn More Here

Pliant Therapeutics Price Quote

$13.83
-0.70 (-4.82%)
(Updated: November 12, 2024 at 5:55 PM ET)

Pliant Therapeutics Key Stats

Buy
52
Pliant Therapeutics (PLRX) is a Buy

Day range:
$14.50 - $15.85
52-week range:
$10.22 - $19.62
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
174.30
P/B ratio:
2.56%

Volume:
326.4K
Avg. volume:
414.5K
1-year change:
5.06%
Market cap:
$884.2M
Revenue:
$1.6M
EPS:
$-3.34

How Much Does Pliant Therapeutics Make?

Data Unavailable

Is Pliant Therapeutics Growing As A Company?

Data Unavailable

Pliant Therapeutics Stock Price Performance

What Is Pliant Therapeutics 52-Week High & Low?

Pliant Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Pliant Therapeutics?

Is Pliant Therapeutics Cash Flow Positive?

  • What Is PLRX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$132.9M
  • What Is Pliant Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $23.2M
  • What Is Pliant Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $133.1M

Pliant Therapeutics Return On Invested Capital

Data Unavailable

Pliant Therapeutics Earnings Date & Stock Price

Pliant Therapeutics Competitors

Pliant Therapeutics Dividend Yield

Pliant Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 3.02%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 40.18
Upside from Last Price: 176.54%

Major Shareholders

  • How many PLRX shares are owned by institutional investors?
    97.8M PLRX shares are owned by institutional investors
  • How many PLRX shares are owned by insiders?
    1.5M PLRX shares are owned by insiders